Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Medtronic/Regeneron

This article was originally published in The Gray Sheet

Executive Summary

Medtronic/Regeneron: Firms enter agreement to co-develop "a family of therapeutics for central nervous system diseases and disorders" using experimental Regeneron compounds and Medtronic delivery systems. The initial project under the agreement will be development of Regeneron's Axokine, delivered using a Medtronic implantable pump, for treatment of Huntington's disease. Under terms of the deal, Medtronic has purchased 460,500 shares of Regeneron common stock for $10 mil. and has acquired five-year warrants to buy another 107,400 shares for $21.72 per share. Regeneron will conduct preclinical development of Axokine and "retains all rights to manufacture and commercialize" the drug. Medtronic, which will make milestone payments to Regeneron during the drug's development, retains rights to manufacture and sell the delivery devices, and will receive royalties on sales of drugs developed under the pact...

You may also be interested in...

Moderna Ready To File Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

Coronavirus Notebook: UK On Cusp Of First Vaccine Approval, Moderna To File mRNA-1273 in US & EU

Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.

Edgewell Finds COVID Bright Side: Wet Ones On Way To Becoming ‘Little Mega-Brand’

Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts